
A company applying Crispr gene-editing technology to treat inherited heart disease is raising $94 million in its second venture funding round. . . . → Read More: Crispr Heart Disease Biotech Raises $94M in New Funds
|
|||||
![]() A company applying Crispr gene-editing technology to treat inherited heart disease is raising $94 million in its second venture funding round. . . . → Read More: Crispr Heart Disease Biotech Raises $94M in New Funds ![]() A group of 15 American universities are putting part of their engineering patents into a common licensing pool for commercial development. . . . → Read More: Universities Form Joint Engineering Patent Pool ![]() A biotechnology enterprise is licensing research from Stanford University on messenger RNA to produce proteins that rejuvenate cells damaged by aging. . . . → Read More: Biotech Licenses mRNA Technology for Aging ![]() Global drug maker Boehringer Ingelheim is gaining access to an immunotherapy technology that targets usually hidden proteins to attack cancer cells. . . . → Read More: Drug Maker Gains Access to Hidden Protein Immunotherapies ![]() A start-up biotechnology company that aims to bring drugs to market at lower cost is raising $500 million in its second venture funding round. . . . → Read More: Drug Price Disruptor Biotech Raises $500M in New Funds ![]() A digital health company is partnering with cancer advocacy organizations to provide electronic therapies to help patients deal with stresses from Covid-19. . . . → Read More: Digital Therapeutics Designed for Cancer/Covid-19 Stress ![]() Drug maker AbbVie is licensing a synthetic antibody to treat Covid-19 and SARS coronaviruses that the company began funding in June. . . . → Read More: AbbVie Acquires Coronavirus Antibody Therapy ![]() A biotechnology company discovering synthetic proteins that target cancer-causing genetic mutations is licensing its lead product to biologics maker Genentech. . . . → Read More: Biotech Licenses Precision Cancer Biologic to Genentech ![]() Results of a clinical trial show a treatment for multiple sclerosis from patients’ stem cells slows progression of the disease and improves walking ability. . . . → Read More: Trial Shows Stem Cell Therapy Slows M.S. Progression ![]() Global drug maker Bayer AG is licensing an engineered T-cell therapy to treat mesothelioma and other solid tumor cancers from biotech Atara Biotherapeutics. . . . → Read More: Bayer Gains Lung Cancer Therapy in $670M Deal |
|||||
Copyright © 2021 Technology News and Literature - All Rights Reserved Powered by WordPress & Atahualpa |